0 CHECKOUT

Sarcoidosis - Pipeline Review, H1 2015

  • ID: 3129728
  • February 2015
  • 59 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Celgene Corporation
  • Johnson & Johnson
  • PharmaIN Corporation
  • Therametrics holding AG
  • MORE

Sarcoidosis - Pipeline Review, H1 2015

Summary

This ‘Sarcoidosis - Pipeline Review, H1 2015’, provides an overview of the Sarcoidosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Sarcoidosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sarcoidosis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by this team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Celgene Corporation
  • Johnson & Johnson
  • PharmaIN Corporation
  • Therametrics holding AG
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Sarcoidosis Overview

Therapeutics Development

Pipeline Products for Sarcoidosis - Overview

Pipeline Products for Sarcoidosis - Comparative Analysis

Sarcoidosis - Therapeutics under Development by Companies

Sarcoidosis - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Sarcoidosis - Products under Development by Companies

Sarcoidosis - Companies Involved in Therapeutics Development

Celgene Corporation

FirstString Research, Inc.

Johnson & Johnson

PharmaIN Corporation

Therametrics holding AG

Sarcoidosis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

apremilast - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CC-220 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

eprodisate disodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

golimumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PGC-VIP - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Synthetic Peptide for Sarcoidosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

thymopentin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Sarcoidosis - Recent Pipeline Updates

Sarcoidosis - Dormant Projects

Sarcoidosis - Discontinued Products

Sarcoidosis - Product Development Milestones

Featured News & Press Releases

Sep 19, 2014: Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics' Kiacta™ Using Crowdsourcing And Telemonitoring

Mar 09, 2011: MondoBIOTECH’s Sarcoidosis Drug Thymopentin Receives Orphan Drug Designation From FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Sarcoidosis, H1 2015

Number of Products under Development for Sarcoidosis - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Comparative Analysis by Early Stage Development, H1 2015

Products under Development by Companies, H1 2015

Sarcoidosis - Pipeline by Celgene Corporation, H1 2015

Sarcoidosis - Pipeline by FirstString Research, Inc., H1 2015

Sarcoidosis - Pipeline by Johnson & Johnson, H1 2015

Sarcoidosis - Pipeline by PharmaIN Corporation, H1 2015

Sarcoidosis - Pipeline by Therametrics holding AG, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Stage and Target, H1 2015

Number of Products by Stage and Mechanism of Action, H1 2015

Number of Products by Stage and Route of Administration, H1 2015

Number of Products by Stage and Molecule Type, H1 2015

Sarcoidosis Therapeutics - Recent Pipeline Updates, H1 2015

Sarcoidosis - Dormant Projects, H1 2015

Sarcoidosis - Discontinued Products, H1 2015

List of Figures

Number of Products under Development for Sarcoidosis, H1 2015

Number of Products under Development for Sarcoidosis - Comparative Analysis, H1 2015

Number of Products under Development by Companies, H1 2015

Comparative Analysis by Clinical Stage Development, H1 2015

Assessment by Monotherapy Products, H1 2015

Number of Products by Top 10 Targets, H1 2015

Number of Products by Stage and Top 10 Targets, H1 2015

Number of Products by Top 10 Mechanism of Actions, H1 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015

Number of Products by Top 10 Routes of Administration, H1 2015

Number of Products by Stage and Top 10 Routes of Administration, H1 2015

Number of Products by Top 10 Molecule Types, H1 2015

Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Celgene Corporation
FirstString Research, Inc.
Johnson & Johnson
PharmaIN Corporation
Therametrics holding AG

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Merck & Co., Inc.
  • Celgene Corporation
  • GlaxoSmithKline PLC
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • ViiV Healthcare